
    
      This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066.
      Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection.

      The study will include the following sequential phases: Screening, Pre-Treatment (Cell
      Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit.
    
  